[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT03373370 : Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology|
|Ages||Min: 51 Years Max: N/A|
- A. Adult (>50 yo)
- Chronic Peripheral neuropathies (progressing since 12 months),
- Peripheral neuropathies documentated by ENMG.
1. Chronic polyneuropathy with dysautonomia (orthostatic hypotension) without
2. Atypical CIDP (situations C, D (even with high protid content on CSF) & E as
defined by the French group for study of CIDP).
3. Disabling neuropathy (gait or balance disorder)
4. Neuropathies with upper limb onset who underwent previously CTS surgery without
5. SLA-like syndrome : areflexia with sensory alterations on ENMG. 6: Deterioration
of SNAPs' amplitudes on NCS > 30% in less than6 months by the same NCS laboratory
Mandatory : A+B+C one of 1 to 6
Exclusion criteria :
- Amyloid deposit characterized on biopsy
- Causes of chronic polyneuropathy : Diabetes mellitus, Chronic alcoholic intoxication
- CIDP responding to IVIg or corticosteroids (improvement by 1 point of ONLS).
- Neuropathy associated with monoclonal gammapathy and i) anti-MAG activity or ii) POEMS
syndrome or) CANOMAD syndrome.
- Ataxic Neuropathy due to vitamine B12 deficiency
- Ataxic Neuropathy due to IgM anti-MAG,
- CANOMAD syndrome,
- Ganglionopathy by Sjögren's syndrome, or paraneoplastic syndrome with Anti- Hu
Antibodies, chemotherapy induced (cis-platine, oxaliplatine).
- Positive family history of FAP or FAC
- Proven AL amyloidosis
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03373370
| Link to official Clinicaltrials.gov listing